Humanigen warns of bankruptcy after failing to bounce back from Covid-19 EUA rejection 

Hu­mani­gen warned in an SEC fil­ing on Tues­day morn­ing that it like­ly won’t sur­vive af­ter its Covid-19 an­ti­body was re­ject­ed by the FDA in fall 2021.

The Short Hills, NJ-based biotech said it is “ex­plor­ing all re­struc­tur­ing op­tions, which may in­clude com­menc­ing a bank­rupt­cy or oth­er in­sol­ven­cy pro­ceed­ing some­time in the third quar­ter of 2023.”

Three Hu­mani­gen board mem­bers al­so re­signed last week, and with that, trad­ing in the com­pa­ny’s shares $HGEN will be sus­pend­ed from to­mor­row.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN